vs

Side-by-side financial comparison of ILLUMINA, INC. (ILMN) and VEON Ltd. (VEON). Click either name above to swap in a different company.

ILLUMINA, INC. is the larger business by last-quarter revenue ($1.1B vs $1.1B, roughly 1.0× VEON Ltd.). VEON Ltd. runs the higher net margin — 55.9% vs 12.3%, a 43.7% gap on every dollar of revenue. On growth, VEON Ltd. posted the faster year-over-year revenue change (5.8% vs 4.8%).

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.

VEON Ltd., also known as VEON Group, is a multinational telecommunication and digital services company. Headquartered in Dubai, the company is publicly traded on the U.S.-based NASDAQ stock exchange. VEON operates in six markets in Europe and Asia, including Bangladesh, Kazakhstan, Kyrgyzstan, Pakistan, Ukraine and Uzbekistan. Specific brands include Banglalink in Bangladesh, Jazz in Pakistan, Kyivstar in Ukraine, and units operating in Kazakhstan, Kyrgyzstan, and Uzbekistan under the Beeline...

ILMN vs VEON — Head-to-Head

Bigger by revenue
ILMN
ILMN
1.0× larger
ILMN
$1.1B
$1.1B
VEON
Growing faster (revenue YoY)
VEON
VEON
+1.0% gap
VEON
5.8%
4.8%
ILMN
Higher net margin
VEON
VEON
43.7% more per $
VEON
55.9%
12.3%
ILMN

Income Statement — Q1 FY2027 vs Q2 FY2025

Metric
ILMN
ILMN
VEON
VEON
Revenue
$1.1B
$1.1B
Net Profit
$134.0M
$608.0M
Gross Margin
66.1%
Operating Margin
19.2%
75.4%
Net Margin
12.3%
55.9%
Revenue YoY
4.8%
5.8%
Net Profit YoY
583.1%
EPS (diluted)
$0.87
$0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ILMN
ILMN
VEON
VEON
Q1 26
$1.1B
Q4 25
$1.2B
Q2 25
$1.1B
Q4 24
$1.1B
Q3 24
$1.1B
Q2 24
$1.1B
$1.0B
Q1 24
$1.1B
Q4 23
$1.1B
Net Profit
ILMN
ILMN
VEON
VEON
Q1 26
$134.0M
Q4 25
$334.0M
Q2 25
$608.0M
Q4 24
$186.0M
Q3 24
$705.0M
Q2 24
$-2.0B
$89.0M
Q1 24
$-126.0M
Q4 23
$-754.0M
Gross Margin
ILMN
ILMN
VEON
VEON
Q1 26
66.1%
Q4 25
65.5%
Q2 25
Q4 24
65.9%
Q3 24
69.0%
Q2 24
64.8%
Q1 24
62.0%
Q4 23
61.1%
Operating Margin
ILMN
ILMN
VEON
VEON
Q1 26
19.2%
Q4 25
17.4%
Q2 25
75.4%
Q4 24
15.8%
Q3 24
68.6%
Q2 24
-147.2%
27.1%
Q1 24
-10.3%
Q4 23
-67.4%
Net Margin
ILMN
ILMN
VEON
VEON
Q1 26
12.3%
Q4 25
28.8%
Q2 25
55.9%
Q4 24
16.8%
Q3 24
65.3%
Q2 24
-178.8%
8.7%
Q1 24
-11.7%
Q4 23
-67.4%
EPS (diluted)
ILMN
ILMN
VEON
VEON
Q1 26
$0.87
Q4 25
$2.16
Q2 25
$0.34
Q4 24
$1.16
Q3 24
$4.42
Q2 24
$-12.48
$0.04
Q1 24
$-0.79
Q4 23
$-4.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ILMN
ILMN
VEON
VEON
Cash + ST InvestmentsLiquidity on hand
$1.2B
$1.3B
Total DebtLower is stronger
Stockholders' EquityBook value
$2.7B
$1.5B
Total Assets
$6.6B
$8.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ILMN
ILMN
VEON
VEON
Q1 26
$1.2B
Q4 25
$1.6B
Q2 25
$1.3B
Q4 24
$93.0M
Q3 24
$70.0M
Q2 24
$74.0M
$862.0M
Q1 24
Q4 23
$6.0M
Stockholders' Equity
ILMN
ILMN
VEON
VEON
Q1 26
$2.7B
Q4 25
$2.7B
Q2 25
$1.5B
Q4 24
$2.4B
Q3 24
$2.1B
Q2 24
$1.4B
$1.1B
Q1 24
$5.7B
Q4 23
$5.9B
Total Assets
ILMN
ILMN
VEON
VEON
Q1 26
$6.6B
Q4 25
$6.6B
Q2 25
$8.5B
Q4 24
$6.3B
Q3 24
$6.0B
Q2 24
$6.1B
$7.3B
Q1 24
$10.0B
Q4 23
$10.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ILMN
ILMN
VEON
VEON
Operating Cash FlowLast quarter
$289.0M
Free Cash FlowOCF − Capex
$251.0M
FCF MarginFCF / Revenue
23.0%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.16×
TTM Free Cash FlowTrailing 4 quarters
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ILMN
ILMN
VEON
VEON
Q1 26
$289.0M
Q4 25
$321.0M
Q2 25
Q4 24
$364.0M
Q3 24
$316.0M
Q2 24
$80.0M
Q1 24
$77.0M
Q4 23
$139.0M
Free Cash Flow
ILMN
ILMN
VEON
VEON
Q1 26
$251.0M
Q4 25
$267.0M
Q2 25
Q4 24
$335.0M
Q3 24
$284.0M
Q2 24
$49.0M
Q1 24
$41.0M
Q4 23
$94.0M
FCF Margin
ILMN
ILMN
VEON
VEON
Q1 26
23.0%
Q4 25
23.0%
Q2 25
Q4 24
30.3%
Q3 24
26.3%
Q2 24
4.4%
Q1 24
3.8%
Q4 23
8.4%
Capex Intensity
ILMN
ILMN
VEON
VEON
Q1 26
Q4 25
Q2 25
Q4 24
2.6%
Q3 24
3.0%
Q2 24
2.8%
Q1 24
3.3%
Q4 23
4.0%
Cash Conversion
ILMN
ILMN
VEON
VEON
Q1 26
2.16×
Q4 25
0.96×
Q2 25
Q4 24
1.96×
Q3 24
0.45×
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ILMN
ILMN

Product revenue$917.0M84%
Service and other revenue$174.0M16%

VEON
VEON

Segment breakdown not available.

Related Comparisons